Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
Viral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-11-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/11/11/1066 |
| _version_ | 1828469624040062976 |
|---|---|
| author | Maki Kiso Seiya Yamayoshi Yuri Furusawa Masaki Imai Yoshihiro Kawaoka |
| author_facet | Maki Kiso Seiya Yamayoshi Yuri Furusawa Masaki Imai Yoshihiro Kawaoka |
| author_sort | Maki Kiso |
| collection | DOAJ |
| description | Viral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. Here, we examined the efficacy of baloxavir marboxil in mice infected with a highly pathogenic human H7N9 virus, A/Guangdong/17SF003/2016. Treatment of infected mice with a single 1.5 mg/kg dose of baloxavir marboxil protected mice from the highly pathogenic human H7N9 virus infection as effectively as oseltamivir treatment at 50 mg/kg twice a day for five days. Daily treatment for five days at 15 or 50 mg/kg of baloxavir marboxil showed superior therapeutic efficacy, largely preventing virus replication in respiratory organs. These results indicate that baloxavir marboxil is a valuable candidate treatment for human patients suffering from highly pathogenic H7N9 virus infection. |
| first_indexed | 2024-12-11T04:41:50Z |
| format | Article |
| id | doaj.art-117a95924f2d4cfc9cc35bdf2ff19b98 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-12-11T04:41:50Z |
| publishDate | 2019-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-117a95924f2d4cfc9cc35bdf2ff19b982022-12-22T01:20:36ZengMDPI AGViruses1999-49152019-11-011111106610.3390/v11111066v11111066Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir MarboxilMaki Kiso0Seiya Yamayoshi1Yuri Furusawa2Masaki Imai3Yoshihiro Kawaoka4Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, JapanViral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. Here, we examined the efficacy of baloxavir marboxil in mice infected with a highly pathogenic human H7N9 virus, A/Guangdong/17SF003/2016. Treatment of infected mice with a single 1.5 mg/kg dose of baloxavir marboxil protected mice from the highly pathogenic human H7N9 virus infection as effectively as oseltamivir treatment at 50 mg/kg twice a day for five days. Daily treatment for five days at 15 or 50 mg/kg of baloxavir marboxil showed superior therapeutic efficacy, largely preventing virus replication in respiratory organs. These results indicate that baloxavir marboxil is a valuable candidate treatment for human patients suffering from highly pathogenic H7N9 virus infection.https://www.mdpi.com/1999-4915/11/11/1066influenzabaloxavir marboxilh7n9highly pathogenic |
| spellingShingle | Maki Kiso Seiya Yamayoshi Yuri Furusawa Masaki Imai Yoshihiro Kawaoka Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil Viruses influenza baloxavir marboxil h7n9 highly pathogenic |
| title | Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil |
| title_full | Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil |
| title_fullStr | Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil |
| title_full_unstemmed | Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil |
| title_short | Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil |
| title_sort | treatment of highly pathogenic h7n9 virus infected mice with baloxavir marboxil |
| topic | influenza baloxavir marboxil h7n9 highly pathogenic |
| url | https://www.mdpi.com/1999-4915/11/11/1066 |
| work_keys_str_mv | AT makikiso treatmentofhighlypathogenich7n9virusinfectedmicewithbaloxavirmarboxil AT seiyayamayoshi treatmentofhighlypathogenich7n9virusinfectedmicewithbaloxavirmarboxil AT yurifurusawa treatmentofhighlypathogenich7n9virusinfectedmicewithbaloxavirmarboxil AT masakiimai treatmentofhighlypathogenich7n9virusinfectedmicewithbaloxavirmarboxil AT yoshihirokawaoka treatmentofhighlypathogenich7n9virusinfectedmicewithbaloxavirmarboxil |